Vraylar 1.5 Mg For Anxiety

[Elenor Waas]

NEWORLEANS -- Low-dose cariprazine (Vraylar) was associated with reductions in anxiety for patients with major depressive disorder (MDD), and the potential adjunctive therapy for this population also demonstrated improvements across most individual symptoms of depression, according to two post hoc analyses of a phase III trial.

When combined with an antidepressant for MDD patients who had an inadequate response to monotherapy, a 1.5-mg daily dose of cariprazine showed a significantly greater reduction in anxiety compared with placebo on the Hamilton Anxiety Rating Scale (HAM-A) total score, as measured by the least squares mean difference (LSMD) from baseline.

At week 6, patients on the 1.5-mg dose had a 9.1 reduction compared with a 7.8 reduction in the placebo group (LSMD -1.30, 95% CI -2.47 to -0.08, nominal P=0.037), reported Vladimir Maletic, MD, MS, of the University of South Carolina School of Medicine in Greenville, during a poster presentation at Psych Congress. No significant difference versus placebo was seen among participants in the trial who received a 3-mg daily dose.

The second analysis, also presented by Maletic, showed significant improvements with cariprazine across eight of the 10 components of the Montgomery-sberg Depression Rating Scale (MADRS) when data for the two doses were pooled together.

"In people who have not responded to their previous antidepressant treatments, if they receive cariprazine [the] indication is that it will provide not only assistance with their depressive symptomatology but will clearly produce reduction in anxiety in patients who have mild and moderate [anxiety]," he told MedPage Today.

Initial findings from the phase III trial -- Study 3111-301-001 -- were reported earlier this year at the American Psychiatric Association annual meeting. The trial met its primary endpoint, demonstrating that adjunctive cariprazine at the lower dose led to a significant reduction in MADRS total score in these patients with MDD.

When the data for the study population was broken into groups based on baseline anxiety severity, participants with at least mild anxiety (HAM-A score >7) or at least moderate anxiety (>14) had better outcomes with the lower dose of cariprazine compared with placebo:

Participants with severe anxiety (>23) at baseline appeared to potentially derive greater benefit with either dose of cariprazine in addition to a background antidepressant, but the findings were not significant, owing to the smaller sample size, according to Maletic.

"We can't say about severe [anxiety] because it's not statistically significant, but at least numerical indicators [show] that all categories of anxious patients are likely to benefit by this combination," he told MedPage Today.

Significant improvements were seen versus placebo with the 1.5-mg daily dose for seven of the 10 MADRS symptoms, and pooled data for both cariprazine doses showed significant reductions in eight of the components:

Cariprazine already carries indications in schizophrenia and bipolar I disorder. Based on the findings of the current study, developer AbbVie has submitted a supplemental new drug application for an additional indication as an adjunctive treatment of MDD in patients who are receiving ongoing antidepressant therapy.

Maletic reported financial relationships with AbbVie/Allergan, Acadia, Alfasigma, Alkermes, Axsome, Eisai-Purdue, Intra-Cellular, Ironshore, Janssen, Lundbeck A/S, Jazz Pharmaceuticals, Noven, Otsuka, Sage, Sunovion, Supernus, and Takeda; co-authors also reported being employees or of holding stock/options in AbbVie.

Dr. Patricia Weiser is a medical writer and drug information expert. She is dedicated to helping people find reliable medical information online, drawing on more than a decade as a community pharmacist. She strives to create evidence-based content that educates and empowers people to take an active role in their healthcare.

Vraylar has a boxed warning for a risk of suicidal thoughts and behaviors in young adults and children. Vraylar also has a boxed warning for an increased risk of death in older adults with psychosis related to dementia. Boxed warnings are serious warnings from the Food and Drug Administration (FDA).

Certain mild side effects of Vraylar usually last a few weeks to months. Examples of these short-term side effects include nausea, upset stomach, headache, and feeling sleepy. Over time, these side effects should ease as your body gets used to the drug. Short-term side effects may return for a time if your doctor increases your dosage.

Akathisia. One of the more common side effects of Vraylar is a movement disorder called akathisia. With akathisia, you feel restless and have an intense urge to move constantly, mainly in your legs. Tell your doctor if you notice this side effect, which may be short or long term. They may decrease your dosage or have you stop taking the drug.

Vraylar is an atypical antipsychotic belonging to a group of drugs called antipsychotics. These drugs are known to cause changes in your metabolism (the way your body converts calories to energy). These changes can lead to weight gain in some people.

Being physically active can help you reach or maintain a moderate weight. But before starting a new workout routine, talk with your doctor. Vraylar may cause problems with regulating body temperature. Too much exercise, especially in hot weather, may raise your risk of heatstroke or overheating while taking Vraylar.

A more severe allergic reaction is rare but possible. Symptoms of a severe allergic reaction can include swelling under your skin, typically in your eyelids, lips, hands, or feet. They can also include swelling of your tongue, mouth, or throat, which can cause trouble breathing.

Keep in mind that consuming a lot of caffeine when you have a mental health condition may cause or worsen certain symptoms. These can include anxiety, mania (high mood), and insomnia (trouble sleeping).

No, Vraylar is not a selective serotonin reuptake inhibitor (SSRI). SSRIs are antidepressants that are used to treat depression and anxiety disorders, among other uses. Vraylar is a kind of drug called an atypical antipsychotic. Vraylar does have some similar effects to an antidepressant and can be used to treat depression. But it does not work the same way as SSRIs do.

Vraylar is also not a controlled substance. A controlled substance is a drug that has a high potential for being misused or causing dependence. Misuse refers to taking a drug in a way other than how your doctor prescribed it, such as taking too much of it. And being dependent on a drug means your body needs it to feel as you usually do.

With bipolar I disorder, you have clear shifts in your moods and behaviors. You have periods of bipolar depression, also called depressive episodes, in which you feel very down, hopeless, or sluggish. Depressive episodes usually last at least 2 weeks.

You also have periods of bipolar mania, also called manic episodes, during which you feel up or extremely energetic. Manic episodes last at least 7 days or become so severe that you need hospital care.

These medications contain different active ingredients, so their side effects vary. That said, both Vraylar and Caplyta have a boxed warning for risk of suicidal thoughts and behaviors in young adults and children. They also have a boxed warning for an increased risk of death in older adults with psychosis related to dementia. Boxed warnings are serious warnings from the Food and Drug Administration (FDA).

There are several important things to discuss with your doctor when considering Vraylar treatment. These include your overall health, any medications or supplements you take, and any medical conditions you have.

Before taking Vraylar, be sure to tell your doctor about all the medications you take, including prescription and over-the-counter types. Also describe any vitamins, herbs, or supplements you use. Your doctor or pharmacist can tell you about any interactions these items may cause with Vraylar.

Vraylar may not be right for you if you have certain medical conditions or other factors that affect your health. Talk with your doctor about your health history before you take Vraylar. Factors to consider include those in the list below.

Drinking alcohol while taking Vraylar could increase your risk of certain side effects from the drug. This is because alcohol and Vraylar may cause some of the same side effects, such as nausea, upset stomach, dizziness, and sleepiness.

If you have certain mental health conditions, your doctor may prescribe Vraylar for you. They can tell you more about the pros and cons of Vraylar, and other treatments for bipolar disorder, major depressive disorder (depression) and schizophrenia.

Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.

The treatment landscape for major depressive disorder (MDD) is evolving. In late 2022, AbbVie (NYSE:ABBV) won FDA approval to use the novel atypical antipsychotic drug Vryalar (cariprazine) as an adjunctive therapy to antidepressants to treat MDD in adults.

The analysis defined the presence or absence of anxiety symptoms with a score of > 7 at baseline on the Hamilton Depression Rating Scale (HAM-D) anxiety/somatization factor. The anxiety/somatization factor comprises six items from the HAM-D, including psychic anxiety, somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, hypochondriasis and insight.

3a8082e126